Takeda allies with Resolve to develop autoimmune disease drugs

03/1/2013 | Genetic Engineering & Biotechnology News

Takeda Pharmaceutical and Resolve Therapeutics agreed to collaborate on treatments for systemic lupus erythematosus and other autoimmune disorders, with an initial focus on Resolve's nuclease Fc fusion protein RSLV-132. The deal gives Takeda an exclusive option to license all Resolve compounds following a study on RSLV-132. Resolve will get $8 million for clinical development, a potential option exercise payment and as much as $247 million in milestone fees plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD